Jazz Pharma forks over $145M to shake off antitrust claims tied to narcolepsy drug Xyrem

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key narcolepsy drug Xyrem with a cool $145 million settlement.

Early this week, the company inked a settlement agreement with a group of indirect purchaser plaintiffs who took the company to court over an alleged "pay-for-delay" arrangement to thwart generic competition to Xyrem. In 2020, the allegations were consolidated into a multidistrict litigation (MDL) case in a North Carolina federal court.